Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Deep Multilayer Tissue Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression, human data

ABSTRACT: The molecular networks underlying Alzheimer’s disease (AD) are not well-defined. We present temporal profiling of >14,000 proteins and >34,000 phosphosites at the asymptomatic and symptomatic stages of AD, deep proteomics analysis of transgenic mouse models.

INSTRUMENT(S): LTQ Orbitrap Elite, Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain

DISEASE(S): Alzheimer's Disease

SUBMITTER: xusheng wang

LAB HEAD: Junmin Peng

PROVIDER: PXD007985 | Pride | 2019-11-11

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Publications

Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer's Disease Progression.

Bai Bing B Wang Xusheng X Li Yuxin Y Chen Ping-Chung PC Yu Kaiwen K Dey Kaushik Kumar KK Yarbro Jay M JM Han Xian X Lutz Brianna M BM Rao Shuquan S Jiao Yun Y Sifford Jeffrey M JM Han Jonghee J Wang Minghui M Tan Haiyan H Shaw Timothy I TI Cho Ji-Hoon JH Zhou Suiping S Wang Hong H Niu Mingming M Mancieri Ariana A Messler Kaitlynn A KA Sun Xiaojun X Wu Zhiping Z Pagala Vishwajeeth V High Anthony A AA Bi Wenjian W Zhang Hui H Chi Hongbo H Haroutunian Vahram V Zhang Bin B Beach Thomas G TG Yu Gang G Peng Junmin J

Neuron 20200108 6

Alzheimer's disease (AD) displays a long asymptomatic stage before dementia. We characterize AD stage-associated molecular networks by profiling 14,513 proteins and 34,173 phosphosites in the human brain with mass spectrometry, highlighting 173 protein changes in 17 pathways. The altered proteins are validated in two independent cohorts, showing partial RNA dependency. Comparisons of brain tissue and cerebrospinal fluid proteomes reveal biomarker candidates. Combining with 5xFAD mouse analysis, ...[more]

PMID: 31926610

Similar Datasets

Whole genome transcriptional analysis of Alzheimer's disease patients compared with age-matched non-demented controls

Project description:Alzheimer’s disease (AD) is an aging related neurodegenerative pathology that affects millions of people worldwide. This pathology has been related to a range of features such as deposition of proteins in the brain, alterations in cell cycle, accumulation of DNA damage, DNA repair deficiency and mitochondrial dysfunction, however the molecular mechanisms implicated in its pathogenesis are still uncertain. Thereby, the present study aimed to evaluate whether peripheral blood mononuclear cells (PBMCs) of AD patients display alterations in gene expression profilescompared to age-matched controls. Blood samples were collected from 25 AD patients and 15 age-matched controls in order to perform genome-wide mRNA expression (microarray). In blood cells, Rank products bioinformatics analysis indicated 593 mRNAs adifferentially expressed in AD compared to controls. Our results demonstrated that PBMCs have alterations in cell cycle and DNA repair as proposed for AD neurons, reinforcing the idea that AD blood cells can provide information about AD status and also can be import as source of studies to better understand the disease.

2017-12-01 | E-MTAB-6094 | biostudies-arrayexpress

Single-cell whole genome sequencing of brain cells of Alzheimerâs disease patients

Project description:We used single-cell whole genome sequencing (scWGS) to assess aneuploidy in isolated neurons from the frontal cortex individuals with mild AD (Braak stage III) and individuals with advanced AD (Braak stage VI). This experiment is related to E-MTAB-4185, which contains control samples.

2016-04-16 | E-MTAB-4184 | biostudies-arrayexpress

Deep Multilayer Tissue Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression

Project description:The molecular networks underlying Alzheimer’s disease (AD) are not well-defined. We present temporal profiling of >14,000 proteins and >34,000 phosphosites at the asymptomatic and symptomatic stages of AD, deep proteomics analysis of transgenic mouse models.

2019-11-11 | PXD007974 | Pride

Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression

2020-04-16 | PXD018590 | Pride

miRNA PCR Array of cortex tissue from Alzheimer disease (AD), high pathological control (HPC) and normal (CTL)subjects

Project description:These data assess the levels of microRNAs via miRNA array in brain tissue from control, high pathological controls, and Alzheimer disease subjects curated from the Rush cohort

2019-11-22 | E-MTAB-8283 | biostudies-arrayexpress

Quantitative PTM Maps of Human Pathologic Tau Identify Patient Heterogeneity and Define Critical Steps in Alzheimer’s Disease Progression - high/low molecular weight tau

Project description:To elucidate the role of Tau isoforms and PTM stoichiometry in Alzheimer’s disease (AD), we generated a high resolution quantitative proteomic map of 88 PTMs on multiple isoforms of Tau isolated from the post-mortem human tissue from 49 AD and 42 control subjects. While Tau PTM maps reveal heterogeneity across subjects, a subset of PTMs display high occupancy and patient frequency for AD suggesting importance in disease. Unsupervised analyses indicate that PTMs occur in an ordered manner leading to Tau aggregation. The processive addition and minimal set of PTMs associated with seeding activity was further defined by the analysis of size fractionated Tau. To summarize, critical features within the Tau protein for disease intervention at different stages of disease are identified, including enrichment of 0N and 4R isoforms, underrepresentation of the C-terminal, an increase in negative charge in the PRR and a decrease in positive charge in the MBD.

2020-12-04 | PXD020483 | Pride

Olfactory bulb proteome characterization in APP/PS1 mice

Project description:Here we used double-transgenic amyloid precursor protein/presenilin 1 (APPswe/PS1dE9) mice and label-free quantitative proteomics to analyze potential early pathological effects on the olfactory bulb (OB) during AD progression.

2016-08-09 | PXD003683 | Pride

The Transglutaminase-2 interactome in the APP23 mouse model of Alzheimer disease

Project description:Amyloid-beta (Aβ) deposition in the brain, is closely linked to development of Alzheimer’s disease (AD). Unfortunately, therapies specifically targeting Aβ deposition have failed to reach their primary clinical endpoints, emphasizing the need to broaden the search strategy for identification of alternative therapeutic targets/mechanisms. Transglutaminase (TG2) catalyses posttranslational modifications, is present in characteristic AD lesions and has AD-associated proteins, including Aβ, tau and apolipoprotein E. However, an unbiased overview of TG2 interactors (TG2 interactome) and the cellular pathways of which these interactors are part in control and AD brain is lacking. Here, anticipating future studies in AD brain, we aimed to identify these interactors and their pathways using a crossbred of the AD-mimicking APP23 mouse model with wildtype and TG2-/- mice. We found that absence of TG2 had no (statistically) significant effect on Aβ pathology, soluble brain levels of Aβ1-40, Aβ1-42, and mRNA levels of TG2 family members compared to APP23 mice. Quantitative proteomics and network analysis revealed a large cluster of TG2 interactors with synaptic transmission/assembly and cell adhesion typical of AD in the APP23 brain. Comparative proteomics were in line with these observations as it also revealed association of proteins of both pathways to be linked to TG2 in APP23 brains Together, our data showed that TG2 deletion led to considerable network alterations consistent with a role of TG2 in (dys)regulation of synaptic transmission and cell adhesion in APP23 brains.

2022-02-22 | PXD030354 | Pride

Quantitative PTM Maps of Human Pathologic Tau Identify Patient Heterogeneity and Define Critical Steps in Alzheimer’s Disease Progression - frontal gyrus (sarkosyl soluble)

2020-12-04 | PXD020717 | Pride

Quantitative proteomic characterization of senile plaques from Alzheimer's disease and non-demented brain

Project description:The deposition of amyloid senile plaques (SPs) play a central role in Alzheimer’s disease (AD), but the mechanisms by which SPs induce neural toxicity are disputed. Genetically engineered mouse models emphasising SPs have had limited success in reproducing the neuropathology of AD, and have also failed to be good indicators of successful amyloid-targeting therapies. Moreover, elderly people with a heavy plaque burden can show normal cognition. Therefore, it is fundamentally important to fully characterize and distinguish the pathological changes elicited by SPs in human and mouse brains. Using laser capture microdissection (LCM) combined with high-throughput mass spectrometry, we quantified ~5000 proteins with high confidence in SPs and non-plaque regions from AD and non-AD human postmortem brain. We found proteomic alteration in SPs is more evident than in non-plaque regions, and identified more than 30 human that are significantly enriched in SPs. We found that AD SPs elicited much more extensive proteomic alterations compared to non-AD SPs. Together, our findings represent the most systematic analysis of sub-proteome of senile plaques and provide a framework for future studies on plaque pathology and AD progression.

2019-02-18 | PXD005824 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data